⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Open Access

Development of an aptamer PEGylation platform for the treatment of infections caused by multidrug-resistant bacteria (MDR)

Juliana Bárbara Silva Souza Daylane Velasco Paula Cruz Camila Câmara Vinícius Gonçalves Camila Faria Elza Figueira José Hernandez José Senna Ivna Silveira

View Full Paper

Ask AI

Bookmark

Share

Key Points

To develop a new platform using aptamer PEGylation for treating infections from multidrug-resistant bacteria.
Development of a PEGylation platform using aptamers.
Evaluation of treatment efficacy against multidrug-resistant bacterial strains.
Demonstrated effective bacterial growth inhibition in treated samples.
Achieved significant reduction in infection severity compared to control cases.

Implication

Demonstrates treatment efficacy in multidrug-resistant bacteria, suggesting a novel therapeutic approach.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Souza et al. (2026) studied this question.

synapsesocial.com/papers/69fece83b9154b0b82875de9 https://doi.org/10.35259/isi.2026_76203

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Advancing the multivalent vaccine horizon: development of bicistronic self-amplifying RNA platforms for next-generation immunobiologicalsOriginal Research · 2026
2Development of nanoparticles for blood–brain barrier crossing in the treatment of neurodegenerative diseasesOriginal Research · 2026
3Impact of enrofloxacin treatment on culture-based and molecular detection of bacterial agents in laboratory miceOriginal Research · 2026
4Cellular immunological mechanisms induced by messenger RNA vaccineOriginal Research · 2026
5Method qualification for the assessment of mRNA vaccine encapsulation efficiencyOriginal Research · 2026

A scalable automated framework for validating antibody-antigen recognition through thermal stability2026
Bio-Manguinhos and new generation of vaccines: consolidation of mRNA-LNP production and evaluation of critical quality attributes at pilot scale2026
Evaluation of a stabilizing agent in messenger RNA vaccines for logistical application in Brazil2026